GRI
GRI Bio, Inc.
Price Chart
Latest Quote
$1.58
+0.10 (+6.76%)
Current Price
| Previous Close | $1.48 |
| Open | $1.51 |
| Day High | $1.63 |
| Day Low | $1.49 |
| Volume | 33,197 |
Stock Information
| Shares Outstanding | 2.19M |
| Total Debt | $44K |
| Cash Equivalents | $10.95M |
| Net Income | $-9.66M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | $3.45M |
| EPS (TTM) | $-14.71 |
| Exchange | NCM |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $-7.62M |
| Income | $-9.66M |
| Book/sh | $4.70 |
| Cash/sh | $5.01 |
| Employees | 3 |
Financial Ratios
| Quick Ratio | 9.95 |
| Current Ratio | 10.30 |
| Debt/Eq | 0.43 |
Returns & Margins
| ROA | -70.93% |
| ROE | -142.02% |
Ownership
| Insider Ownership | 0.38% |
| Institutional Ownership | 4.28% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| Forward P/E | -0.79 |
| P/B | 0.34 |
Analyst Data
| Recommendation | strong_buy |
| Target Price | $18.50 |
Technical Indicators
| SMA20 | $1.63 |
| SMA50 | $1.83 |
| SMA200 | $2.31 |
| RSI | 34.83 |
| ATR | 0.1246 |
| Shares Float | 2.19M |
| Short Float | 3.18% |
| Short Ratio | 0.13 |
| Volatility | -0.61 |
| Rel Volume | 0.75 |
Performance History
| Week | +8.22% |
| Month | -24.76% |
| Quarter | +7.48% |
| 6 Months | -33.05% |
| YTD | -79.85% |
| Year | -97.25% |
| 3 Years | -100.00% |
| 5 Years | -100.00% |
| 10 Years | -100.00% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-10-27 | $1.58 | 33,197 |
| 2026-10-26 | $1.50 | 11,800 |
| 2026-10-23 | $1.45 | 64,900 |
| 2026-10-22 | $1.42 | 102,300 |
| 2026-10-21 | $1.47 | 59,000 |
| 2026-10-20 | $1.46 | 46,700 |
| 2026-10-19 | $1.45 | 42,600 |
| 2026-10-16 | $1.38 | 44,300 |
| 2026-10-15 | $1.40 | 28,500 |
| 2026-10-14 | $1.40 | 50,500 |
| 2026-10-13 | $1.55 | 28,900 |
| 2026-10-12 | $1.57 | 64,500 |
| 2026-10-09 | $1.74 | 21,300 |
| 2026-10-08 | $1.68 | 54,500 |
| 2026-10-07 | $1.85 | 31,500 |
| 2026-10-06 | $1.90 | 18,200 |
| 2026-10-05 | $1.91 | 84,600 |
| 2026-10-02 | $1.96 | 38,400 |
| 2026-10-01 | $1.96 | 20,300 |
| 2026-09-30 | $1.93 | 35,400 |
| 2026-09-29 | $2.00 | 25,600 |
| 2026-09-28 | $2.10 | 118,100 |
About GRI Bio, Inc.
GRI Bio, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing therapies that target diseases leading to inflammatory, fibrotic, and autoimmune disorders in the United States. Its lead product candidate is GRI-0621, an oral inhibitor of type 1 Natural Killer T cells, which is in phase IIa clinical trial for the treatment of severe fibrotic lung diseases, such as idiopathic pulmonary fibrosis. The company's portfolio also includes GRI-0803, a novel oral agonist of type 2 Natural Killer T cells that is in preclinical development for the treatment of autoimmune disorders; a proprietary library of 500+ compounds; and GRI-0124 and GRI-0729 for balance inflammatory immune responses. The company was formerly known as Glycoregimmune, Inc. GRI Bio, Inc. was founded in 2009 and is based in LA Jolla, California.
đ° Latest News
No news articles available at the moment. Check back later for updates on GRI.
Period:
Loading...
Income Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Revenue | ||||
| Total Revenue | $0 | $0 | $0 | $0 |
| Operating Revenue | $0 | $0 | $0 | $0 |
| Expenses | ||||
| Total Expenses | $11,977,000 | $8,235,000 | $11,387,000 | $2,239,000 |
| Net Non Operating Interest Income Expense | $21,000 | $25,000 | $-2,082,000 | $-653,000 |
| Operating Expense | $11,977,000 | $8,235,000 | $11,387,000 | $2,239,000 |
| General And Administrative Expense | $5,158,000 | $4,467,000 | $8,155,000 | $1,997,000 |
| Other Income Expense | - | $3,000 | $432,000 | $-325,000 |
| Other Non Operating Income Expenses | - | $3,000 | $432,000 | - |
| Interest Expense | - | - | $2,082,000 | $653,000 |
| Interest Expense Non Operating | - | - | $2,082,000 | $653,000 |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $-11,956,000 | $-8,207,000 | $-13,037,000 | $-3,217,000 |
| Net Interest Income | $21,000 | $25,000 | $-2,082,000 | $-653,000 |
| Interest Income | $21,000 | $25,000 | - | - |
| Normalized Income | $-11,956,000 | $-8,207,000 | $-13,037,000 | $-2,892,000 |
| Net Income From Continuing And Discontinued Operation | $-11,956,000 | $-8,207,000 | $-13,037,000 | $-3,217,000 |
| Total Operating Income As Reported | $-11,977,000 | $-8,235,000 | $-11,387,000 | $-2,239,000 |
| Net Income Common Stockholders | $-11,956,000 | $-10,118,000 | $-13,037,000 | $-3,217,000 |
| Net Income | $-11,956,000 | $-8,207,000 | $-13,037,000 | $-3,217,000 |
| Net Income Including Noncontrolling Interests | $-11,956,000 | $-8,207,000 | $-13,037,000 | $-3,217,000 |
| Net Income Continuous Operations | $-11,956,000 | $-8,207,000 | $-13,037,000 | $-3,217,000 |
| Pretax Income | $-11,956,000 | $-8,207,000 | $-13,037,000 | $-3,217,000 |
| Interest Income Non Operating | $21,000 | $25,000 | - | - |
| Operating Income | $-11,977,000 | $-8,235,000 | $-11,387,000 | $-2,239,000 |
| Special Income Charges | - | - | $0 | $-325,000 |
| Per Share | ||||
| Diluted EPS | $-121.80 | $-1545.55 | $-125355.77 | $-47308.82 |
| Basic EPS | $-121.80 | $-1545.55 | $-125355.77 | $-47308.82 |
| Other | ||||
| Tax Effect Of Unusual Items | $0 | $0 | $0 | $0 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-11,973,000 | $-8,231,000 | $-10,951,000 | $-2,236,000 |
| Reconciled Depreciation | $4,000 | $4,000 | $4,000 | $3,000 |
| EBITDA (Bullshit earnings) | $-11,973,000 | $-8,231,000 | $-10,951,000 | $-2,561,000 |
| EBIT | $-11,977,000 | $-8,235,000 | $-10,955,000 | $-2,564,000 |
| Diluted Average Shares | $98,161 | $6,546 | $104 | $68 |
| Basic Average Shares | $98,161 | $6,546 | $104 | $68 |
| Diluted NI Availto Com Stockholders | $-11,956,000 | $-10,118,000 | $-13,037,000 | $-3,217,000 |
| Otherunder Preferred Stock Dividend | $0 | $1,911,000 | - | - |
| Research And Development | $6,819,000 | $3,768,000 | $3,232,000 | $242,000 |
| Selling General And Administration | $5,158,000 | $4,467,000 | $8,155,000 | $1,997,000 |
| Other Gand A | $5,158,000 | $4,467,000 | $8,155,000 | $1,997,000 |
| Total Unusual Items | - | - | $182,000 | $-325,000 |
| Total Unusual Items Excluding Goodwill | - | - | $182,000 | $-325,000 |
| Gain On Sale Of Security | - | - | $182,000 | - |
| Other Special Charges | - | - | - | $325,000 |
Fetched: 2026-10-26
Balance Sheet (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $6,008,000 | $4,032,000 | $259,000 | $-1,625,000 |
| Total Assets | $8,666,000 | $5,739,000 | $2,956,000 | $383,000 |
| Total Non Current Assets | $74,000 | $124,000 | $22,000 | $71,000 |
| Current Assets | $8,592,000 | $5,615,000 | $2,934,000 | $312,000 |
| Other Current Assets | $363,000 | $587,000 | $1,126,000 | $303,000 |
| Cash Cash Equivalents And Short Term Investments | $8,229,000 | $5,028,000 | $1,808,000 | $9,000 |
| Cash And Cash Equivalents | $8,229,000 | $5,028,000 | $1,808,000 | $9,000 |
| Cash Financial | $8,229,000 | $5,028,000 | $1,808,000 | $9,000 |
| Non Current Prepaid Assets | - | - | - | $4,000 |
| Debt | ||||
| Total Debt | $71,000 | $119,000 | $14,000 | $673,000 |
| Long Term Debt And Capital Lease Obligation | $15,000 | $71,000 | $0 | $14,000 |
| Current Debt And Capital Lease Obligation | $56,000 | $48,000 | $14,000 | $659,000 |
| Net Debt | - | - | - | $593,000 |
| Current Debt | - | - | - | $602,000 |
| Other Current Borrowings | - | - | - | - |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $2,658,000 | $1,707,000 | $2,697,000 | $2,008,000 |
| Total Non Current Liabilities Net Minority Interest | $15,000 | $71,000 | $0 | $14,000 |
| Current Liabilities | $2,643,000 | $1,636,000 | $2,697,000 | $1,994,000 |
| Payables And Accrued Expenses | $2,587,000 | $1,588,000 | $2,680,000 | $1,330,000 |
| Payables | $1,837,000 | $897,000 | $1,410,000 | $1,294,000 |
| Accounts Payable | $1,837,000 | $897,000 | $1,410,000 | $1,294,000 |
| Other Current Liabilities | - | - | $3,000 | - |
| Current Deferred Liabilities | - | - | $0 | $5,000 |
| Current Notes Payable | - | - | $0 | $602,000 |
| Interest Payable | - | - | - | $0 |
| Equity | ||||
| Common Stock Equity | $6,008,000 | $4,032,000 | $259,000 | $-1,625,000 |
| Total Equity Gross Minority Interest | $6,008,000 | $4,032,000 | $259,000 | $-1,625,000 |
| Stockholders Equity | $6,008,000 | $4,032,000 | $259,000 | $-1,625,000 |
| Retained Earnings | $-51,696,000 | $-39,740,000 | $-31,533,000 | $-18,496,000 |
| Other | ||||
| Ordinary Shares Number | $497,692 | $18,767 | $104 | $68 |
| Share Issued | $497,692 | $18,767 | $104 | $68 |
| Tangible Book Value | $6,008,000 | $4,032,000 | $259,000 | $-1,625,000 |
| Invested Capital | $6,008,000 | $4,032,000 | $259,000 | $-1,023,000 |
| Working Capital | $5,949,000 | $3,979,000 | $237,000 | $-1,682,000 |
| Capital Lease Obligations | $71,000 | $119,000 | $14,000 | $71,000 |
| Total Capitalization | $6,008,000 | $4,032,000 | $259,000 | $-1,625,000 |
| Additional Paid In Capital | $57,704,000 | $43,772,000 | $31,792,000 | $16,871,000 |
| Capital Stock | $0 | $0 | $0 | $0 |
| Common Stock | $0 | $0 | $0 | $0 |
| Long Term Capital Lease Obligation | $15,000 | $71,000 | $0 | $14,000 |
| Current Capital Lease Obligation | $56,000 | $48,000 | $14,000 | $57,000 |
| Current Accrued Expenses | $750,000 | $691,000 | $1,270,000 | $36,000 |
| Net PPE | $74,000 | $124,000 | $22,000 | $71,000 |
| Accumulated Depreciation | $-34,000 | $-30,000 | $-26,000 | $-22,000 |
| Gross PPE | $108,000 | $154,000 | $48,000 | $93,000 |
| Other Properties | $71,000 | $120,000 | $14,000 | $67,000 |
| Machinery Furniture Equipment | $37,000 | $34,000 | $34,000 | $26,000 |
| Pensionand Other Post Retirement Benefit Plans Current | - | - | - | $33,000 |
Fetched: 2026-10-26
Cash Flow Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $-10,189,000 | $-8,611,000 | $-8,998,000 | $-1,088,000 |
| Operating Activities | ||||
| Operating Cash Flow | $-10,186,000 | $-8,611,000 | $-8,990,000 | $-1,085,000 |
| Cash Flow From Continuing Operating Activities | $-10,186,000 | $-8,611,000 | $-8,990,000 | $-1,085,000 |
| Operating Gains Losses | - | $-3,000 | $-182,000 | $325,000 |
| Investing Activities | ||||
| Capital Expenditure | $-3,000 | - | $-8,000 | $-3,000 |
| Investing Cash Flow | $-3,000 | $0 | $-8,000 | $-3,000 |
| Cash Flow From Continuing Investing Activities | $-3,000 | $0 | $-8,000 | $-3,000 |
| Financing Activities | ||||
| Repurchase Of Capital Stock | $-1,000 | $-1,000 | $0 | $-124,000 |
| Issuance Of Capital Stock | $15,560,000 | $13,103,000 | $12,250,000 | $0 |
| Financing Cash Flow | $13,390,000 | $11,831,000 | $10,797,000 | $1,007,000 |
| Cash Flow From Continuing Financing Activities | $13,390,000 | $11,831,000 | $10,797,000 | $1,007,000 |
| Net Other Financing Charges | $-2,169,000 | $-2,033,000 | $-2,715,000 | $-119,000 |
| Net Common Stock Issuance | $15,559,000 | $13,102,000 | $12,250,000 | $-124,000 |
| Common Stock Issuance | $15,560,000 | $13,103,000 | $12,250,000 | $0 |
| Other | ||||
| End Cash Position | $8,229,000 | $5,028,000 | $1,808,000 | $9,000 |
| Beginning Cash Position | $5,028,000 | $1,808,000 | $9,000 | $90,000 |
| Changes In Cash | $3,201,000 | $3,220,000 | $1,799,000 | $-81,000 |
| Proceeds From Stock Option Exercised | $0 | $762,000 | $12,000 | $0 |
| Common Stock Payments | $-1,000 | $-1,000 | $0 | $-124,000 |
| Net PPE Purchase And Sale | $-3,000 | $0 | $-8,000 | $-3,000 |
| Purchase Of PPE | $-3,000 | $0 | $-8,000 | $-3,000 |
| Change In Working Capital | $925,000 | $-448,000 | $1,680,000 | $1,515,000 |
| Change In Other Current Liabilities | $-48,000 | $105,000 | $-57,000 | $-43,000 |
| Change In Payables And Accrued Expense | $722,000 | $-866,000 | $2,284,000 | $1,593,000 |
| Change In Accrued Expense | $59,000 | $-479,000 | $125,000 | $696,000 |
| Change In Payable | $663,000 | $-387,000 | $2,159,000 | $897,000 |
| Change In Account Payable | $663,000 | $-387,000 | $2,159,000 | $897,000 |
| Change In Prepaid Assets | $251,000 | $313,000 | $-547,000 | $-35,000 |
| Other Non Cash Items | $48,000 | $-105,000 | $2,157,000 | $217,000 |
| Stock Based Compensation | $793,000 | $148,000 | $388,000 | $25,000 |
| Depreciation Amortization Depletion | $4,000 | $4,000 | $4,000 | $3,000 |
| Depreciation And Amortization | $4,000 | $4,000 | $4,000 | $3,000 |
| Depreciation | $4,000 | $4,000 | $4,000 | $3,000 |
| Net Income From Continuing Operations | $-11,956,000 | $-8,207,000 | $-13,037,000 | $-3,217,000 |
| Issuance Of Debt | - | $0 | $1,250,000 | $1,500,000 |
| Net Issuance Payments Of Debt | - | $0 | $1,250,000 | $1,250,000 |
| Net Short Term Debt Issuance | - | $0 | $1,250,000 | $1,250,000 |
| Short Term Debt Issuance | - | $0 | $1,250,000 | $1,500,000 |
| Gain Loss On Investment Securities | - | $-3,000 | $-182,000 | - |
| Repayment Of Debt | - | - | $0 | $-250,000 |
| Interest Paid Supplemental Data | - | - | $0 | $33,000 |
| Short Term Debt Payments | - | - | $0 | $-250,000 |
| Asset Impairment Charge | - | - | $53,000 | $47,000 |
| Net Long Term Debt Issuance | - | - | - | $1,250,000 |
| Long Term Debt Payments | - | - | - | $-125,000 |
| Long Term Debt Issuance | - | - | - | $1,375,000 |
Fetched: 2026-10-26